Association of ABO blood groups with venous thrombosis recurrence in middle-aged patients: insights from a weighted Cox analysis dedicated to ambispective design.
ABO blood groups
Ambispective design
Genetic association studies
Recurrence
Survival analysis
Venous thrombosis
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
22 04 2023
22 04 2023
Historique:
received:
11
04
2022
accepted:
04
04
2023
medline:
25
4
2023
pubmed:
23
4
2023
entrez:
22
04
2023
Statut:
epublish
Résumé
In studies of time-to-events, it is common to collect information about events that occurred before the inclusion in a prospective cohort. When the studied risk factors are independent of time, including both pre- and post-inclusion events in the analyses, generally referred to as relying on an ambispective design, increases the statistical power but may lead to a selection bias. In the field of venous thromboembolism (VT), ABO blood groups have been the subject of extensive research due to their substantial effect on VT risk. However, few studies have investigated their effect on the risk of VT recurrence. Motivated by the study of the association of genetically determined ABO blood groups with VT recurrence, we propose a methodology to include pre-inclusion events in the analysis of ambispective studies while avoiding the selection bias due to mortality. This work relies on two independent cohorts of VT patients, the French MARTHA study built on an ambispective design and the Dutch MEGA study built on a standard prospective design. For the analysis of the MARTHA study, a weighted Cox model was developed where weights were defined by the inverse of the survival probability at the time of data collection about the events. Thanks to the collection of information on the vital status of patients, we could estimate the survival probabilities using a delayed-entry Cox model on the death risk. Finally, results obtained in both studies were then meta-analysed. In the combined sample totalling 2,752 patients including 993 recurrences, the A1 blood group has an increased risk (Hazard Ratio (HR) of 1.18, p = 4.2 × 10 The proposed methodology increases the power of studies relying on an ambispective design which is frequent in epidemiologic studies about recurrent events. This approach allowed to clarify the association of ABO blood groups with the risk of VT recurrence. Besides, this methodology has an immediate field of application in the context of genome wide association studies.
Sections du résumé
BACKGROUND
In studies of time-to-events, it is common to collect information about events that occurred before the inclusion in a prospective cohort. When the studied risk factors are independent of time, including both pre- and post-inclusion events in the analyses, generally referred to as relying on an ambispective design, increases the statistical power but may lead to a selection bias. In the field of venous thromboembolism (VT), ABO blood groups have been the subject of extensive research due to their substantial effect on VT risk. However, few studies have investigated their effect on the risk of VT recurrence. Motivated by the study of the association of genetically determined ABO blood groups with VT recurrence, we propose a methodology to include pre-inclusion events in the analysis of ambispective studies while avoiding the selection bias due to mortality.
METHODS
This work relies on two independent cohorts of VT patients, the French MARTHA study built on an ambispective design and the Dutch MEGA study built on a standard prospective design. For the analysis of the MARTHA study, a weighted Cox model was developed where weights were defined by the inverse of the survival probability at the time of data collection about the events. Thanks to the collection of information on the vital status of patients, we could estimate the survival probabilities using a delayed-entry Cox model on the death risk. Finally, results obtained in both studies were then meta-analysed.
RESULTS
In the combined sample totalling 2,752 patients including 993 recurrences, the A1 blood group has an increased risk (Hazard Ratio (HR) of 1.18, p = 4.2 × 10
CONCLUSION
The proposed methodology increases the power of studies relying on an ambispective design which is frequent in epidemiologic studies about recurrent events. This approach allowed to clarify the association of ABO blood groups with the risk of VT recurrence. Besides, this methodology has an immediate field of application in the context of genome wide association studies.
Identifiants
pubmed: 37087423
doi: 10.1186/s12874-023-01915-7
pii: 10.1186/s12874-023-01915-7
pmc: PMC10122291
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Informations de copyright
© 2023. The Author(s).
Références
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Blood. 2021 Apr 29;137(17):2394-2402
pubmed: 33512453
J Thromb Thrombolysis. 2021 Feb;51(2):494-501
pubmed: 32594420
PLoS One. 2011;6(9):e25581
pubmed: 21980494
BMJ Open. 2014;4(8):e005438
pubmed: 25232560
Blood. 2011 Mar 31;117(13):3692-4
pubmed: 21270443
Blood Adv. 2022 Dec 27;6(24):6274-6281
pubmed: 35416922
Circulation. 2022 Oct 18;146(16):1225-1242
pubmed: 36154123
Thromb Haemost. 2013 Dec;110(6):1172-9
pubmed: 24067945
Science. 2018 Aug 24;361(6404):769-773
pubmed: 30072576
Nat Genet. 2019 Nov;51(11):1574-1579
pubmed: 31676865
J Thromb Haemost. 2006 Dec;4(12):2587-92
pubmed: 17059428
J Med Econ. 2011;14(1):65-74
pubmed: 21222564
Ann Hematol. 2017 Mar;96(3):383-386
pubmed: 27766390
Thromb Res. 2015 Jul;136(1):107-11
pubmed: 25981188
Blood. 2009 May 21;113(21):5298-303
pubmed: 19278955
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Circulation. 2003 Jun 17;107(23 Suppl 1):I4-8
pubmed: 12814979
Nat Rev Cardiol. 2015 Aug;12(8):464-74
pubmed: 26076949
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k
pubmed: 25173341
Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):298-310
pubmed: 19228602
Int J Epidemiol. 2015 Feb;44(1):324-33
pubmed: 25501468
Epidemiology. 2004 Sep;15(5):615-25
pubmed: 15308962
Am J Trop Med Hyg. 2019 Oct;101(4):812-820
pubmed: 31452498
Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):341-2
pubmed: 13679670
Thromb Haemost. 2000 May;83(5):657-60
pubmed: 10823257
Thromb Haemost. 2013 Dec;110(6):1110-1
pubmed: 24136686
Blood. 2019 Nov 7;134(19):1645-1657
pubmed: 31420334
Lifetime Data Anal. 2010 Oct;16(4):580-98
pubmed: 20526806
CMAJ. 2013 Mar 19;185(5):E229-37
pubmed: 23382263
Stat Med. 1991 Dec;10(12):1931-41
pubmed: 1805319
Br J Haematol. 2012 Apr;157(2):230-9
pubmed: 22443383
J Thromb Thrombolysis. 2019 Feb;47(2):216-226
pubmed: 30368761
Lancet. 2003 Aug 16;362(9383):523-6
pubmed: 12932383
J Thromb Haemost. 2016 Sep;14(9):1798-802
pubmed: 27326655
Diabetes Care. 2008 Nov;31(11):2154-9
pubmed: 18782902
Thromb Haemost. 2014 Dec;112(6):1103-9
pubmed: 25187297
Am J Hum Genet. 2015 Apr 2;96(4):532-42
pubmed: 25772935
Epidemiology. 2000 Sep;11(5):561-70
pubmed: 10955409